The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Myocardial Fibrosis Market Research Report 2025
Synopsis
Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling,nausea and fatigue.Myocardial fibrosis, also known as myocardial calcification, is the result of sustained myocardial fiber and/or repeated aggravation of myocardial ischemia and hypoxia caused by moderate to severe coronary atherosclerotic stenosis, leading to the progressive development of heart failure with IHD, or chronic ischemic heart disease
The global Myocardial Fibrosis market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Myocardial Fibrosis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Myocardial Fibrosis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Myocardial Fibrosis in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Myocardial Fibrosis include Merck, Evotec AG, Miragen Therapeutics, TRACON Pharmaceuticals, Daewoong Pharmaceutical, Galectin Therapeutics, GTx, Invivosciences and Lead Discovery Center, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Myocardial Fibrosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myocardial Fibrosis.
Report Scope
The Myocardial Fibrosis market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Myocardial Fibrosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myocardial Fibrosis companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Evotec AG
Miragen Therapeutics
TRACON Pharmaceuticals
Daewoong Pharmaceutical
Galectin Therapeutics
GTx
Invivosciences
Lead Discovery Center
MandalMed
Segment by Type
Small Molecule Therapeutic Modality
Protein Therapeutic Modality
Peptide Therapeutic Modality
Endoglin Antibody Therapeutic Modality
Stem Cell Therapeutic Modality
RNA Therapeutic Modality
Other
Segment by Application
Hospital
Clinics
Research Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Myocardial Fibrosis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling,nausea and fatigue.Myocardial fibrosis, also known as myocardial calcification, is the result of sustained myocardial fiber and/or repeated aggravation of myocardial ischemia and hypoxia caused by moderate to severe coronary atherosclerotic stenosis, leading to the progressive development of heart failure with IHD, or chronic ischemic heart disease
The global Myocardial Fibrosis market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Myocardial Fibrosis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Myocardial Fibrosis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Myocardial Fibrosis in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Myocardial Fibrosis include Merck, Evotec AG, Miragen Therapeutics, TRACON Pharmaceuticals, Daewoong Pharmaceutical, Galectin Therapeutics, GTx, Invivosciences and Lead Discovery Center, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Myocardial Fibrosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myocardial Fibrosis.
Report Scope
The Myocardial Fibrosis market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Myocardial Fibrosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myocardial Fibrosis companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Evotec AG
Miragen Therapeutics
TRACON Pharmaceuticals
Daewoong Pharmaceutical
Galectin Therapeutics
GTx
Invivosciences
Lead Discovery Center
MandalMed
Segment by Type
Small Molecule Therapeutic Modality
Protein Therapeutic Modality
Peptide Therapeutic Modality
Endoglin Antibody Therapeutic Modality
Stem Cell Therapeutic Modality
RNA Therapeutic Modality
Other
Segment by Application
Hospital
Clinics
Research Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Myocardial Fibrosis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myocardial Fibrosis Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Small Molecule Therapeutic Modality
1.2.3 Protein Therapeutic Modality
1.2.4 Peptide Therapeutic Modality
1.2.5 Endoglin Antibody Therapeutic Modality
1.2.6 Stem Cell Therapeutic Modality
1.2.7 RNA Therapeutic Modality
1.2.8 Other
1.3 Market by Application
1.3.1 Global Myocardial Fibrosis Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Research Laboratories
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myocardial Fibrosis Market Perspective (2019-2030)
2.2 Myocardial Fibrosis Growth Trends by Region
2.2.1 Global Myocardial Fibrosis Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Myocardial Fibrosis Historic Market Size by Region (2019-2024)
2.2.3 Myocardial Fibrosis Forecasted Market Size by Region (2025-2030)
2.3 Myocardial Fibrosis Market Dynamics
2.3.1 Myocardial Fibrosis Industry Trends
2.3.2 Myocardial Fibrosis Market Drivers
2.3.3 Myocardial Fibrosis Market Challenges
2.3.4 Myocardial Fibrosis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myocardial Fibrosis Players by Revenue
3.1.1 Global Top Myocardial Fibrosis Players by Revenue (2019-2024)
3.1.2 Global Myocardial Fibrosis Revenue Market Share by Players (2019-2024)
3.2 Global Myocardial Fibrosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myocardial Fibrosis Revenue
3.4 Global Myocardial Fibrosis Market Concentration Ratio
3.4.1 Global Myocardial Fibrosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myocardial Fibrosis Revenue in 2023
3.5 Myocardial Fibrosis Key Players Head office and Area Served
3.6 Key Players Myocardial Fibrosis Product Solution and Service
3.7 Date of Enter into Myocardial Fibrosis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myocardial Fibrosis Breakdown Data by Type
4.1 Global Myocardial Fibrosis Historic Market Size by Type (2019-2024)
4.2 Global Myocardial Fibrosis Forecasted Market Size by Type (2025-2030)
5 Myocardial Fibrosis Breakdown Data by Application
5.1 Global Myocardial Fibrosis Historic Market Size by Application (2019-2024)
5.2 Global Myocardial Fibrosis Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Myocardial Fibrosis Market Size (2019-2030)
6.2 North America Myocardial Fibrosis Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Myocardial Fibrosis Market Size by Country (2019-2024)
6.4 North America Myocardial Fibrosis Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myocardial Fibrosis Market Size (2019-2030)
7.2 Europe Myocardial Fibrosis Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Myocardial Fibrosis Market Size by Country (2019-2024)
7.4 Europe Myocardial Fibrosis Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myocardial Fibrosis Market Size (2019-2030)
8.2 Asia-Pacific Myocardial Fibrosis Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Myocardial Fibrosis Market Size by Region (2019-2024)
8.4 Asia-Pacific Myocardial Fibrosis Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myocardial Fibrosis Market Size (2019-2030)
9.2 Latin America Myocardial Fibrosis Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Myocardial Fibrosis Market Size by Country (2019-2024)
9.4 Latin America Myocardial Fibrosis Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myocardial Fibrosis Market Size (2019-2030)
10.2 Middle East & Africa Myocardial Fibrosis Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Myocardial Fibrosis Market Size by Country (2019-2024)
10.4 Middle East & Africa Myocardial Fibrosis Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Myocardial Fibrosis Introduction
11.1.4 Merck Revenue in Myocardial Fibrosis Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Evotec AG
11.2.1 Evotec AG Company Detail
11.2.2 Evotec AG Business Overview
11.2.3 Evotec AG Myocardial Fibrosis Introduction
11.2.4 Evotec AG Revenue in Myocardial Fibrosis Business (2019-2024)
11.2.5 Evotec AG Recent Development
11.3 Miragen Therapeutics
11.3.1 Miragen Therapeutics Company Detail
11.3.2 Miragen Therapeutics Business Overview
11.3.3 Miragen Therapeutics Myocardial Fibrosis Introduction
11.3.4 Miragen Therapeutics Revenue in Myocardial Fibrosis Business (2019-2024)
11.3.5 Miragen Therapeutics Recent Development
11.4 TRACON Pharmaceuticals
11.4.1 TRACON Pharmaceuticals Company Detail
11.4.2 TRACON Pharmaceuticals Business Overview
11.4.3 TRACON Pharmaceuticals Myocardial Fibrosis Introduction
11.4.4 TRACON Pharmaceuticals Revenue in Myocardial Fibrosis Business (2019-2024)
11.4.5 TRACON Pharmaceuticals Recent Development
11.5 Daewoong Pharmaceutical
11.5.1 Daewoong Pharmaceutical Company Detail
11.5.2 Daewoong Pharmaceutical Business Overview
11.5.3 Daewoong Pharmaceutical Myocardial Fibrosis Introduction
11.5.4 Daewoong Pharmaceutical Revenue in Myocardial Fibrosis Business (2019-2024)
11.5.5 Daewoong Pharmaceutical Recent Development
11.6 Galectin Therapeutics
11.6.1 Galectin Therapeutics Company Detail
11.6.2 Galectin Therapeutics Business Overview
11.6.3 Galectin Therapeutics Myocardial Fibrosis Introduction
11.6.4 Galectin Therapeutics Revenue in Myocardial Fibrosis Business (2019-2024)
11.6.5 Galectin Therapeutics Recent Development
11.7 GTx
11.7.1 GTx Company Detail
11.7.2 GTx Business Overview
11.7.3 GTx Myocardial Fibrosis Introduction
11.7.4 GTx Revenue in Myocardial Fibrosis Business (2019-2024)
11.7.5 GTx Recent Development
11.8 Invivosciences
11.8.1 Invivosciences Company Detail
11.8.2 Invivosciences Business Overview
11.8.3 Invivosciences Myocardial Fibrosis Introduction
11.8.4 Invivosciences Revenue in Myocardial Fibrosis Business (2019-2024)
11.8.5 Invivosciences Recent Development
11.9 Lead Discovery Center
11.9.1 Lead Discovery Center Company Detail
11.9.2 Lead Discovery Center Business Overview
11.9.3 Lead Discovery Center Myocardial Fibrosis Introduction
11.9.4 Lead Discovery Center Revenue in Myocardial Fibrosis Business (2019-2024)
11.9.5 Lead Discovery Center Recent Development
11.10 MandalMed
11.10.1 MandalMed Company Detail
11.10.2 MandalMed Business Overview
11.10.3 MandalMed Myocardial Fibrosis Introduction
11.10.4 MandalMed Revenue in Myocardial Fibrosis Business (2019-2024)
11.10.5 MandalMed Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
